@neurologyadvisor.bsky.socialWeekly #gefurulimab was well tolerated and demonstrated early and sustained clinical benefit among adults with anti–acetylcholine receptor antibody-positive generalized #MyastheniaGravis.
https://www.neurologyadvisor.com/news/weekly-gefurulimab-myasthenia-gravis-outcomes/